Ivonescimab combined with chemotherapy shows promising efficacy in an ALK fusion-positive lung adenocarcinoma patient with ALK-TKI resistance: a case report
Meiyuan Lin, Yuan Gao, Jun Deng · 2025
Read Ivonescimab combined with chemotherapy shows promising efficacy in an ALK fusion-positive lung adenocarcinoma patient with ALK-TKI resistance: a case report by Meiyuan Lin, Yuan Gao, Jun Deng (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12756029.txt.
Description
Meiyuan Lin, Yuan Gao, and Jun Deng published a case report in 2025 on one lung cancer patient. The tumor carried a gene fusion that often responds to targeted pills. The patient also had high levels of a marker tied to immune therapy response. Two targeted pills were tried in turn.
Both pills failed fast, with the cancer growing again within a short span. Fresh gene tests guided the switch each time. The team then gave a dual-action antibody drug plus standard chemotherapy. That mix brought a good response in this patient. The authors say this is the first report of that drug in such a case. They offer it as a lead for doctors facing the same drug resistance.
Catalog record
| CREATOR | Meiyuan Lin, Yuan Gao, Jun Deng |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 18 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |